246 related articles for article (PubMed ID: 31560045)
1. Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease.
Abu-Sbeih H; Wang Y
Inflamm Bowel Dis; 2020 Apr; 26(5):662-668. PubMed ID: 31560045
[TBL] [Abstract][Full Text] [Related]
2. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management.
Abu-Sbeih H; Ali FS; Wang Y
Curr Opin Gastroenterol; 2020 Jan; 36(1):25-32. PubMed ID: 31609734
[TBL] [Abstract][Full Text] [Related]
3. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis.
Ibraheim H; Baillie S; Samaan MA; Abu-Sbeih H; Wang Y; Talley NJ; P Jones M; Powell N
Aliment Pharmacol Ther; 2020 Nov; 52(9):1432-1452. PubMed ID: 32920854
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
5. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
[TBL] [Abstract][Full Text] [Related]
6. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis.
Powell N; Ibraheim H; Raine T; Speight RA; Papa S; Brain O; Green M; Samaan MA; Spain L; Yousaf N; Hunter N; Eldridge L; Pavlidis P; Irving P; Hayee B; Turajlic S; Larkin J; Lindsay JO; Gore M
Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):679-697. PubMed ID: 32553146
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab.
Alexander JL; Ibraheim H; Sheth B; Little J; Khan MS; Richards C; Hunter N; Chauhan D; Ratnakumaran R; McHugh K; Pinato DJ; Nathan P; Choy J; Crusz SM; Furness A; Turajlic S; Pickering L; Larkin J; Teare JP; Papa S; Speight A; Sharma A; Powell N
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34233964
[TBL] [Abstract][Full Text] [Related]
8. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review.
Collins M; Soularue E; Marthey L; Carbonnel F
Clin Gastroenterol Hepatol; 2020 May; 18(6):1393-1403.e1. PubMed ID: 32007539
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy induced enterocolitis and gastritis - What to do and when?
Cheung VTF; Brain O
Best Pract Res Clin Gastroenterol; 2020; 48-49():101703. PubMed ID: 33317787
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.
Gong Z; Wang Y
JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors-Induced Colitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():151-157. PubMed ID: 30539510
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.
Prieux-Klotz C; Dior M; Damotte D; Dreanic J; Brieau B; Brezault C; Abitbol V; Chaussade S; Coriat R
Target Oncol; 2017 Jun; 12(3):301-308. PubMed ID: 28540478
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease.
Shirwaikar Thomas A; Hanauer S; Wang Y
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):878-890. PubMed ID: 36270617
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report.
Holmstroem RB; Dahl EK; Helms M; Nielsen HV; Andersen JB; Bjerrum JT; Svane IM; Ellebaek E; Seidelin JB
BMJ Open Gastroenterol; 2022 Dec; 9(1):. PubMed ID: 36581371
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review.
Ma C; MacDonald JK; Nguyen TM; Vande Casteele N; Linggi B; Lefevre P; Wang Y; Feagan BG; Jairath V
Dig Dis Sci; 2022 Apr; 67(4):1128-1155. PubMed ID: 33770330
[TBL] [Abstract][Full Text] [Related]
18. Use of Vedolizumab in Immune Checkpoint Inhibitor-associated Enterocolitis.
Stone ML; Forster EM
Inflamm Bowel Dis; 2021 Nov; 27(12):e147. PubMed ID: 34244730
[No Abstract] [Full Text] [Related]
19. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Dougan M
Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
[TBL] [Abstract][Full Text] [Related]
20. Serious immune-related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series.
Bresteau C; Bonnet P; Robert C; Mussini C; Saiag P; Buecher B; Lebbe C; Allez M; Benamouzig R; Hagège H; Bécheur H; Meyer A; Carbonnel F
J Gastroenterol Hepatol; 2023 Dec; 38(12):2104-2110. PubMed ID: 37710354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
